Top News Stories November 14 2017

The day’s top news stories from stocks on the GuerillaStockTrading watch list.
Continue reading “Top News Stories November 14 2017”

Top News Stories For November 13 2017

The day’s top news stories from stocks on the GuerillaStockTrading watch list.
Continue reading “Top News Stories For November 13 2017”

Top Weekend News Stories November 11 – 12, 2017

The top news stories this weekend from stocks on the GuerillaStockTrading watch list.
Continue reading “Top Weekend News Stories November 11 – 12, 2017”

Top Earnings Beats For the Week Ending November 10 2017

Below are the top earnings and/or revenue beats for the week ending November 10, 2017. The table below is sorted by the biggest beats in descending order (at the top).
Continue reading “Top Earnings Beats For the Week Ending November 10 2017”

Intercept Pharmaceuticals Rising Large Players Volume

Intercept Pharmaceuticals stock sold off on an FDA warning letter at the end of the quarter. Since, large players volume has been rising while the stock has formed a basing pattern.

Intercept Pharmaceuticals has rising large players volume while the stock has formed a basing pattern. This is a very bullish technical setup.
Continue reading “Intercept Pharmaceuticals Rising Large Players Volume”

Bluebird Bio Stock Strong Uptrend On Buy Ratings

While Bluebird Bio stock doesn’t look like a good entry right now, they are advancing a CAR T treatment that looks extremely promising.

Bluebird Bio stock is in a strong uptrend as the number of analysts with Buy ratings surge.

BTIG upgraded Bluebird Bio stock from Neutral to Buy, and set a price target of $177. BTIG thinks that positive signals are coming from the FDA concerning bluebird bio’s latest CAR-T therapy for advanced stage multiple myeloma patients. Earlier this year, bluebird bio’s precursor to bb21217, named bb2121, delivered a 100% response rate among 15 multiple myeloma patients.
Continue reading “Bluebird Bio Stock Strong Uptrend On Buy Ratings”

Progenics Pharmaceuticals 142 Percent Price Target From Cantor Fitzgerald

Cantor Fitzgerald really went out high on Progenics Pharmaceuticals, or did they? Needham and Company also gave this stock its highest Strong Buy rating too.

Progenics Pharmaceuticals had its price target set to $15 by Cantor Fitzgerald. Cantor Fitzgerald has a Buy rating on the stock. Cantor Fitzgerald has struggled over the last year with its performance; however, Needham and Company hasn’t.
Continue reading “Progenics Pharmaceuticals 142 Percent Price Target From Cantor Fitzgerald”

Exelixis Beats On Earnings and Revenue For Good Setup

Exelixis absolutely crushed earnings and revenue estimates! Even better, the stock has been pulling back over the last couple of weeks making for a good entry.

Exelixis stock is a good setup as its been pulling back and now the company has just reported earnings and revenue beats. Exelixis crushed it by reporting EPS of $0.26 versus the $0.05 estimate. Revenue also crushed it with $152.50 million during the quarter versus the $104.91 million estimate. Revenue grew a whopping 145.2% year-over-year.
Continue reading “Exelixis Beats On Earnings and Revenue For Good Setup”

Neurocrine Biosciences Beats on Earnings and Revenue

Neurocrine Biosciences reported both earnings and revenue beats. This stock is also a good seasonal play.

Neurocrine Biosciences Inc reported EPS of ($0.13) crushing the consensus estimate of ($0.49). Revenue also beat coming in at $60.77 million versus the $29.38 million estimate.
Continue reading “Neurocrine Biosciences Beats on Earnings and Revenue”

Verastem Price Target Set 364 Percent Higher By Cantor Fitzgerald

Verastem stock had a price target set 364% higher than its current price by Cantor Fitzgerald. Cantor Fitzgerald has a buy rating on the stock.

Verastem is on track for duvelisib NDA in Q1 2018, to include accelerated approval request for follicular lymphoma. Duvelisib is a dual inhibitor of two enzymes called phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma. Both are associated with the growth and survival of malignant B cells and T cells.
Continue reading “Verastem Price Target Set 364 Percent Higher By Cantor Fitzgerald”